Ocrevus (Ocrelizumab) in Israel — erhalten Sie 3 personalisierte Klinikempfehlungen

Ocrevus (ocrelizumab) is a monoclonal antibody therapy targeting CD20-positive B-cells to treat multiple sclerosis. It is available in Israel at JCI-accredited centers like Sheba Medical Center and Sourasky Medical Center for relapsing forms of MS and primary progressive MS (PPMS).

• Conditions treated: Approved for relapsing-remitting, active secondary progressive, and primary progressive multiple sclerosis.
• Infusion schedule: Administered as an intravenous infusion every 6 months in outpatient centers.
• Israel pricing: Costs range from $16,500 to $22,800 per treatment cycle.
• Potential savings: Patients save approximately 75% compared to US retail prices of $80,000.
• Clinical timeline: Full therapeutic effects on disability typically become observable within 12 to 24 weeks.

Bookimed Expert Insight: Israel's leadership in neuroimmunology is clear when looking at clinics like Sheba Medical Center, ranked 7th globally. Surgeons like Dr. Arnon Karni at Sourasky bridge the gap between research and practice, having trained in MS immunology at Harvard University. This high level of specialization ensures that patients receiving Ocrevus benefit from protocols used at the world's top-tier institutions.

Patient Consensus: Patients value the convenience of 6-month dosing over daily injections but emphasize using pre-medication to manage infusion-related fatigue. Many stress that patience is vital, as early relapses occasionally occur before the drug reaches full efficacy.

Ocrevus is generally safe for relapsing and primary progressive multiple sclerosis when managed by specialized neurologists. It requires screening for Hepatitis B and regular blood monitoring every 6 months. Patients typically experience 12–24 hours of mild fatigue or soreness following the intravenous infusion sessions.

• Screening requirement: Medical teams must confirm a negative Hepatitis B status before the first dose.
• Infusion monitoring: Clinical staff observe patients during and 1 hour after treatment for reactions.
• B-cell tracking: Clinicians perform blood tests every 6 months to monitor CD20+ B-cell depletion levels.
• Immune health: Doctors check immunoglobulin IgG and IgM levels periodically to ensure immune system stability.

Bookimed Expert Insight: Israeli centers like Sourasky or Sheba utilize neurologists with specialized research backgrounds in neuroimmunology. While the drug is effective, our data shows patients often choose Israel for the 6-month follow-up window. This allows them to combine mandatory IgG monitoring with consultations from global experts like Dr. Arnon Karni.

Patient Consensus: Many feel the risk-benefit profile is favorable compared to letting MS progress. Most report only short-term fatigue and find the twice-yearly schedule more manageable than daily medications.

Ocrevus treatment risk includes infusion-related reactions, most common during the initial dose, and increased susceptibility to infections like respiratory tract issues or shingles. Rare but serious risks involve progressive multifocal leukoencephalopathy (PML), liver injury, and potential malignancies including breast cancer. Patients usually receive steroids and antihistamines beforehand.

• Infusion reactions: Itchy skin, throat irritation, and flushing occur in over 33% of patients.
• Infection risk: B-cell depletion increases vulnerability to colds, bronchitis, and herpes-related infections.
• Severe complications: Doctors monitor for rare occurrences of immune-mediated colitis and liver enzyme elevation.
• Neurological safety: Specialists track B-cell regeneration every 8 months to manage long-term immune health.

Bookimed Expert Insight: Israeli centers like Sheba and Sourasky differentiate their Ocrevus protocols by integrating precision medicine. Dr. Arnon Karni at Sourasky, who studied at Harvard, focuses specifically on neuroimmunology. This expertise helps patients manage pseudo-flares, which are temporary symptom spikes often mistaken for treatment failure in less specialized settings.

Patient Consensus: Expect profound fatigue for about one week following your infusion. Many patients suggest bringing hard candy to mask the bitter taste of medications and reporting any throat tightness to nurses immediately.

Individuals should not take Ocrevus (ocrelizumab) if they have an active hepatitis B infection or have experienced life-threatening infusion reactions. Severe hypersensitivity to ocrelizumab or hyaluronidase is a definitive contraindication. Treatment must be delayed for active infections including respiratory and urinary tract issues.

• Infection status: Active hepatitis B virus (HBV) or unresolved chronic infections prevent starting therapy.
• Infusion history: Previous severe allergic reactions to ocrelizumab require permanent discontinuation of the medication.
• Vaccination timing: Live vaccines are prohibited during treatment and for 1 month before starting.
• Immune deficiency: People with severely low IgG or IgM levels require baseline immune monitoring.

Bookimed Expert Insight: Israeli centers like Sourasky Medical Center (Ichilov) prioritize a specific premedication protocol to bypass infusion sensitivities. Surgeons use a cocktail of Benadryl, Solu-Medrol, Claritin, and Pepcid because managing the infusion environment often allows patients with mild historical reactions to complete treatment safely.

Patient Consensus: Patients emphasize checking for even minor symptoms like a sore throat or UTI before sessions. They report that being infection-free is the biggest factor in avoiding treatment delays or adverse immune responses.

Ocrevus is administered by healthcare professionals through intravenous infusion or subcutaneous injection. The standard protocol involves an initial split-dose regimen of two 300 mg infusions 2 weeks apart. Maintenance doses of 600 mg follow every 6 months to manage multiple sclerosis effectively.

• Administration method: Standard treatment uses a 3.5 to 4 hour intravenous drip infusion.
• Injection alternative: Ocrevus Zunovo offers a 10-minute subcutaneous injection into the abdomen area.
• Pre-medication protocol: Patients receive corticosteroids and antihistamines 30 to 60 minutes before starting infusions.
• Monitoring phase: Clinical staff observe patients for at least 1 hour after each treatment session.

Bookimed Expert Insight: While initial infusions require 4 hours, Israel’s JCI-accredited centers like Sourasky अक्सर provide a shorter 2-hour infusion for maintenance. Expert neurologists like Dr. Arnon Karni, who studied neuroimmunology at Harvard, oversee these protocols to ensure safety during faster administration.

Patient Consensus: Expect to spend a full day at the clinic due to pre-medication and monitoring. Patients recommend staying consistent with the 6-month schedule to prevent disease activity flares.

Ocrevus infusions in Israel typically take 4 to 7 hours total from arrival to discharge. Patients receive intravenous therapy at specialized oncology or neurology centers like Sourasky Medical Center (Ichilov). Procedures never occur in standard exam rooms or at home to ensure patient safety.

• Time breakdown: Allow 5–6 hours for first doses; 4 hours for subsequent maintenance.
• Infusion protocols: Rapid infusions take 2 hours, while standard protocols last 3.5 to 4 hours.
• Mandatory monitoring: Clinical staff observe patients for at least 1 hour post-infusion for reactions.
• Medication phase: Pre-medications including steroids and antihistamines require 30 to 60 minutes before starting.

Bookimed Expert Insight: While private clinics like Herzliya Medical Center offer tailored VIP service, large state facilities like Sheba Medical Center handle over 1.9 million patients annually. This high volume often means nurses and neurologists like Dr. Arnon Karni have unparalleled experience managing rare infusion reactions efficiently.

Patient Consensus: Plan for a full half-day and treat the session like a long flight by bringing entertainment. Pre-medications often cause drowsiness, so patients strongly recommend arranging a driver for the trip home.

Ocrevus (ocrelizumab) is included in Israel's national health basket (Sal HaBriut) for multiple sclerosis treatment. Coverage applies through the four national HMOs (Kupot Holim) for patients meeting specific clinical indications. Administrative approval from a medical committee is often required before beginning therapy.

• Coverage scope: State-subsidized for patients meeting criteria for primary or relapsing-remitting multiple sclerosis.
• Provider network: Available through Clalit, Maccabi, Meuhedet, and Leumit HMOs at certified medical centers.
• Administrative process: Neuroimmunology specialists must submit specific clinical documentation for medical committee review.
• Cost structure: Patients typically pay capped quarterly copayments for medication and infusion services.

Bookimed Expert Insight: Israeli centers like Sheba Medical Center are evolving from traditional drug distribution to precision research. Sheba is currently developing CAR-T therapies specifically for severe autoimmune diseases. This shifts the focus from simply managing symptoms to regenerating the immune system, often providing alternatives if Ocrevus is not suitable.

Patient Consensus: Individuals emphasize that even while Ocrevus is technically in the basket, you should prepare for administrative hurdles. Consulting a neurologist at a specialized center like Sourasky (Ichilov) helps ensure your documentation meets strict Ministry of Health criteria.